NCT05667779View on ClinicalTrials.gov

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

December 27, 2023

Study Completion Date

December 27, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

QRL-101

Single-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.

OTHER

Placebo

A placebo comparator will be administered at all dose levels.

Trial Locations (1)

9728 NZ

ICON plc. Van Swietenlaan 6, Groningen

All Listed Sponsors
lead

QurAlis Corporation

INDUSTRY